Abstract 4819
Background
Previously, studies showed the distribution of radiation-induced lung injury (RIL) pattern after stereotactic body radiotherapy (SBRT) of non-small cell lung cancer (NSCLC). However, few analysis data were from China.
Methods
106 lung cancer patients who were treated with SBRT were included, their computed tomography (CT) scans were reviewed. Late injury pattern was classified by Koening’s, radiation lung fibrosis was classified by CTC 5.0, radiologists’ diagnosis for RIL was analyze. Fisher exact test was used for correlation analysis.
Results
Radiographic late injury within at least 6 months after SBRT was concluded. The majority of late RIL pattern was mass-like, not the modified conventional pattern. 36.8% patients showed acute injury. The median time for the occurrence of late injury was 8 months and 4 months for acute injury. Only per fraction dose and the occurrence of acute injury were correlated with different late injury pattern. No grade 2-5 lung fibrosis was observed. 24.5% RIL cases were misdiagnosed to tumor progression by radiologists. Most misdiagnosis occurred among mass-like pattern. We observed 13 patients with atelectasis which may be due to the irradiation of proximal bronchial tree (PBT).
Conclusions
SBRT for lung cancer patients was safe, the majority of late RIL was mass-like pattern. Higher per fraction dose and the occurrence of acute injury were related with mass-like injury pattern. This injury was difficult to be distinguished from tumor progression, which leaded to misdiagnosis of 24.5% patients receiving SBRT. Moreover, the irradiated dose to PBT may be related to the atelectasis after SBRT.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Shanghai Chest Hospital, Shanghai Jiao Tong University.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2728 - MicroRNA expression and DNA methylation profiles do not distinguish between primary and recurrent well-differentiated liposarcoma
Presenter: Melissa Vos
Session: Poster Display session 1
Resources:
Abstract
3197 - Genomic Alterations, Tumor Mutation Burden and Prognosis of Chinese Cardiac Sarcoma Patients
Presenter: Na Zhu
Session: Poster Display session 1
Resources:
Abstract
4214 - Evaluation of a peptide-conjugated alkylator melflufen in osteosarcoma preclinical models
Presenter: Konstantin Byrgazov
Session: Poster Display session 1
Resources:
Abstract
2654 - Expression analysis of NHEJ and HR genes in Ewing sarcomas: indications of DSB repair dysfunction
Presenter: Anastasios Kyriazoglou
Session: Poster Display session 1
Resources:
Abstract
4383 - Epidemiology of Synovial Sarcoma in EU28 countries
Presenter: Nedra Joseph
Session: Poster Display session 1
Resources:
Abstract
1937 - Resection Of High-Grade Large Soft Tissue Sarcoma With Adequate Wide Margin Can Lead To Good Local Control Without Adjuvant Radiotherapy
Presenter: Toshiyuki Kunisada
Session: Poster Display session 1
Resources:
Abstract
3757 - Influence of eribulin on proliferation, migration and invasion properties of leiomyosarcoma cell line models
Presenter: Marta Mendiola
Session: Poster Display session 1
Resources:
Abstract
1040 - EREMISS: Efficacy of regorafenib (REG) as maintenance therapy in non-adipocytic soft tissue sarcomas (STS) having received 1st-line doxorubicin-based chemotherapy (Doxo-CT)
Presenter: Nicolas Penel
Session: Poster Display session 1
Resources:
Abstract
1048 - A Phase 2 biomarker-driven study evaluating the clinical efficacy of an MDM2 inhibitor, milademetan, in patients with intimal sarcoma, a disease with a high unmet need
Presenter: Kan Yonemori
Session: Poster Display session 1
Resources:
Abstract
1511 - A pilot study of oral paclitaxel (ORAXOL) in subjects with cutaneous angiosarcomas (KX-ORAX-010)
Presenter: Herbert Loong
Session: Poster Display session 1
Resources:
Abstract